Literature DB >> 9736584

In vitro activity of the new glycopeptide LY333328 against multiply resistant gram-positive clinical isolates.

F García-Garrote1, E Cercenado, L Alcalá, E Bouza.   

Abstract

The in vitro activity of LY333328 was compared with those of vancomycin and teicoplanin against 425 gram-positive clinical isolates, including a variety of multiply resistant strains. LY333328 at </=4 microgram/ml inhibited all microorganisms tested, including methicillin- and teicoplanin-resistant staphylococci, glycopeptide-resistant enterococci, penicillin- and multiply resistant pneumococci, and viridans and beta-hemolytic streptococci.

Entities:  

Mesh：

Substances：

Year:  1998        PMID： 9736584      PMCID： PMC105854     

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  10 in total

1.  In vitro activity of LY333328, an investigational glycopeptide antibiotic, against enterococci and staphylococci.

Authors:  R S Schwalbe; A C McIntosh; S Qaiyumi; J A Johnson; R J Johnson; K M Furness; W J Holloway; L Steele-Moore
Journal:  Antimicrob Agents Chemother       Date:  1996-10       Impact factor: 5.191

2.  Comparative activities of LY 333328, a new glycopeptide, against penicillin-susceptible and -resistant pneumococci.

Authors:  E Fasola; S K Spangler; L M Ednie; M R Jacobs; S Bajaksouzian; P C Appelbaum
Journal:  Antimicrob Agents Chemother       Date:  1996-11       Impact factor: 5.191

3.  Time-kill curves for a semisynthetic glycopeptide, LY333328, against vancomycin-susceptible and vancomycin-resistant Enterococcus faecium strains.

Authors:  S A Zelenitsky; J A Karlowsky; G G Zhanel; D J Hoban; T Nicas
Journal:  Antimicrob Agents Chemother       Date:  1997-06       Impact factor: 5.191

4.  Pharmacodynamic evaluation of a new glycopeptide, LY333328, and in vitro activity against Staphylococcus aureus and Enterococcus faecium.

Authors:  R C Mercier; H H Houlihan; M J Rybak
Journal:  Antimicrob Agents Chemother       Date:  1997-06       Impact factor: 5.191

Review 5.  Methicillin-resistant staphylococci: detection methods and treatment of infections.

Authors:  C J Hackbarth; H F Chambers
Journal:  Antimicrob Agents Chemother       Date:  1989-07       Impact factor: 5.191

6.  Semisynthetic glycopeptide antibiotics derived from LY264826 active against vancomycin-resistant enterococci.

Authors:  T I Nicas; D L Mullen; J E Flokowitsch; D A Preston; N J Snyder; M J Zweifel; S C Wilkie; M J Rodriguez; R C Thompson; R D Cooper
Journal:  Antimicrob Agents Chemother       Date:  1996-09       Impact factor: 5.191

7.  In vitro activity and spectrum of LY333328, a novel glycopeptide derivative.

Authors:  R N Jones; M S Barrett; M E Erwin
Journal:  Antimicrob Agents Chemother       Date:  1997-02       Impact factor: 5.191

8.  In vitro antibacterial activity of LY333328, a new semisynthetic glycopeptide.

Authors:  F Biavasco; C Vignaroli; R Lupidi; E Manso; B Facinelli; P E Varaldo
Journal:  Antimicrob Agents Chemother       Date:  1997-10       Impact factor: 5.191

9.  Secular trends in nosocomial primary bloodstream infections in the United States, 1980-1989. National Nosocomial Infections Surveillance System.

Authors:  S N Banerjee; T G Emori; D H Culver; R P Gaynes; W R Jarvis; T Horan; J R Edwards; J Tolson; T Henderson; W J Martone
Journal:  Am J Med       Date:  1991-09-16       Impact factor: 4.965

10.  Nosocomial enterococci resistant to vancomycin--United States, 1989-1993.

Authors: 
Journal:  MMWR Morb Mortal Wkly Rep       Date:  1993-08-06       Impact factor: 17.586
  10 in total
  13 in total

1.  Activity of LY333328 in experimental meningitis caused by a Streptococcus pneumoniae strain susceptible to penicillin.

Authors:  J Gerber; A Smirnov; A Wellmer; J Ragheb; J Prange; E Schütz; K Wettich; S Kalich; R Nau
Journal:  Antimicrob Agents Chemother       Date:  2001-07       Impact factor: 5.191

2.  Vancomycin-Resistant Enterococcus: Infectious Endocarditis Treatment.

Authors: 
Journal:  Curr Infect Dis Rep       Date:  1999-06       Impact factor: 3.725

Review 3.  Telavancin: a novel semisynthetic lipoglycopeptide agent to counter the challenge of resistant Gram-positive pathogens.

Authors:  Biswadeep Das; Chayna Sarkar; Debasmita Das; Amit Gupta; Arnav Kalra; Shubham Sahni
Journal:  Ther Adv Infect Dis       Date:  2017-03-08

4.  New drugs to treat skin and soft tissue infections.

Authors:  Gary E Stein
Journal:  Curr Infect Dis Rep       Date:  2007-09       Impact factor: 3.725

5.  In vitro activities of LY333328 and comparative agents against nosocomial gram-positive pathogens collected in a 1997 global surveillance study.

Authors:  M L Zeckel; D A Preston; B S Allen
Journal:  Antimicrob Agents Chemother       Date:  2000-05       Impact factor: 5.191

6.  Endocarditis Caused by Highly Penicillin-Resistant Viridans Group Streptococci: Still Room for Vancomycin-Based Regimens.

Authors:  Juan M Pericàs; Ruvandhi Nathavitharana; Cristina Garcia-de-la-Mària; Carles Falces; Juan Ambrosioni; Manel Almela; Javier García-González; Eduard Quintana; Francesc Marco; Asunción Moreno; Arnold S Bayer; José M Miró; Adolf W Karchmer
Journal:  Antimicrob Agents Chemother       Date:  2019-07-25       Impact factor: 5.191

7.  In vitro and in vivo activities of tigecycline (GAR-936), daptomycin, and comparative antimicrobial agents against glycopeptide-intermediate Staphylococcus aureus and other resistant gram-positive pathogens.

Authors:  Peter J Petersen; Patricia A Bradford; William J Weiss; Timothy M Murphy; P E Sum; Steven J Projan
Journal:  Antimicrob Agents Chemother       Date:  2002-08       Impact factor: 5.191

Review 8.  Glycopeptide antibiotics: from conventional molecules to new derivatives.

Authors:  Françoise Van Bambeke; Yves Van Laethem; Patrice Courvalin; Paul M Tulkens
Journal:  Drugs       Date:  2004       Impact factor: 9.546

9.  Effect of polysorbate 80 on oritavancin binding to plastic surfaces: implications for susceptibility testing.

Authors:  Francis F Arhin; Ingrid Sarmiento; Adam Belley; Geoffrey A McKay; Deborah C Draghi; Parveen Grover; Daniel F Sahm; Thomas R Parr; Gregory Moeck
Journal:  Antimicrob Agents Chemother       Date:  2008-02-25       Impact factor: 5.191

10.  Experimental study of LY333328 (oritavancin), alone and in combination, in therapy of cephalosporin-resistant pneumococcal meningitis.

Authors:  Carmen Cabellos; Antonio Fernàndez; Jose M Maiques; Fe Tubau; Carmen Ardanuy; Pedro F Viladrich; Josefina Liñares; Francesc Gudiol
Journal:  Antimicrob Agents Chemother       Date:  2003-06       Impact factor: 5.191
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.